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usually leaves patients with no treatment options. Autolo-
gous bone marrow cells may have potential to reduce the
instances of amputation and improve quality of life for these
patients.
Methods: 49 patients with thromboangitis obliterans
resulting in CLI were treated with a composition of con-
centrated bone marrow nucleated cells. A total of 240 mL
of aspirate was processed using a point of care centrifuge
(Harvest Technologies, Plymouth, MA) to yield 40 mL of
treating volume. The patients were divided equally into two
treatment groups. Group 1 received forty 1 mL direct
intramuscular injections in the ischemic regions below the
knee and Group 2 received twenty 1 mL direct intramus-
cular injections below the knee and an intra-arterial infu-
sion of 20 mL down the SFA into the lower leg. An
evaluation of these patients was conducted at 12 and 26
weeks.
Results: All patients enrolled were men with the fol-
lowing demographics: mean age 44.9, all smokers. There
were six adverse events in each treatment group. None were
considered to be related to the biologic treatment. No
patients died. Limb salvage was 87.5% and all major end-
points showed statistically significant improvement over
baseline: Quality of Life assessment (Rand-36 question-
naire) p0.0009; perception of pain p0.0001; TcPO2
and ABI measurement p0.0001 & p 0.0003 respec-
tively. There was 100% reduction in pain medications.
Mean number of nucleated cells delivered 3.63x10. The
delivery method showed no statistical difference.
Conclusions: Based on these results, this bone marrow
composition may be considered safe and has shown poten-
tial to reduce amputation rates. This study has also shown
that both the methods of delivery are equally effective and
safe.
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Objectives: Congestive heart failure (CHF) predicts
morbidity and mortality after treatment of peripheral arte-
rial disease. The impact on procedural success, however,
remains unknown. We hypothesized that CHF with re-
duced left ventricular ejection fraction (LVEF) results in a
diminished perfusion pressure and a low-flow state that
could predispose arterial interventions to fail.
Methods: A prospective database identified patients
with CHF who underwent endovascular arterial interven-
tion from 2004-2009. Demographics, co-morbidities, in-
tervention, LVEF, and outcomes were recorded. Patients
were followed clinically and by duplex ultrasound. Kaplan-
Meier survival analysis and Cox Regression were used.
Results: Of 1220 patients undergoing intervention,
271 patients (22%) with documented CHF underwent
intervention for claudication (23%) or critical limb ischemia
(CLI) (77%). Primary patency at 1 year was 51.92.5%
among those with CHF, compared to 64.61.3% in con-
trols (p0.001). In the setting of CHF, 1 year patency was
56.64.1% if LVEF40% vs 43.23.5% if LVEF40%
(p0.001). (Table 1). Among those with CLI, limb sal-
vage rates were equivalent between controls and patients
with CHF and LVEF40%, but worse with LVEF40%
(p0.01) and LVEF20% (p0.001).
Conclusions: CHF is an independent risk factor for
failure of endovascular intervention. Specifically, low LVEF
(40%) predicts loss of patency. The inverse association
between patency and LVEF needs further assessment.
Table 1. Primary Patency
Patency at
12 months
Patency at
24 months
Patency at
36 months
Control 64.6  1.3 53.1  1.4 47.5  1.6
CHF 51.9  2.5 42.8  2.7 38.5  2.8
LVEF40% 56.6  4.1 45.9  4.4 36.0  4.8
LVEF40% 43.2  3.5 26.9  3.7 16.8  4.9
P-Values
Control vs CHF .001* .001* .001*
Control vs CHF
(LVEF40%)
.001* .001* .001*
Control vs CHF
(LVEF40%)
0.03* 0.051 0.057
LVEF40% vs
LVEF40%
0.008* .001* .001*
*Statistically Significant.
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Video Presentation
Endovascular Management of an Aorto-Iliac Occlusion
Utilizing an IVUS Guided Re-entry Device
Ali Amin. Surgery, Reading Hospital and Medical Center,
Reading, PA
Background: 43 yr old female. pain bilateral lower
extremity for 8 months. Pain worse right side, can only
walk few feet. pain at night, chronic numbness right foot.
Hypertension, COPD, HIV smoker Absent femoral/
pedal pulses. ABI right .36 left .64 Abdominal duplex:
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